轻度持续性支气管哮喘患儿单用孟鲁司特的疗效

Effectiveness of Montelukast as Mono-Controller on Mild Persistent Asthma in Children

目的评估在实际生活条件影响下轻度持续性支气管哮喘(哮喘)患儿单独使用孟鲁司特进行控制治疗的效果。方法选取2～14岁在社区进行治疗的轻度持续哮喘患儿,进行前瞻性、单组、非盲观察性研究。孟鲁司特每天1次,2～5岁年龄组每次4 mg,6～14岁年龄组每次5 mg,持续12周,患儿通过监护人员给药,采取门诊复诊、随访的方式进行治疗及评估。分别在研究的0、4、8、12周,对过去7 d的日间症状、夜间症状进行严重程度评分,对峰值流速(PEF)、短效β2受体激动剂使用量进行检测和记录。采用SPSS 16.0统计软件进行统计分析。结果 2个年龄组日间症状、夜间症状严重程度评分在各随访时间点的评分逐步降低,各相邻时间点均数差异有统计学意义(P<0.05);短期使用短效β2受体激动剂的量明显下降,从第0周到第4周观察到显著的减少量(P<0.05);PEF不断改善,终点观察值(第12周)与起始值(第0周)比较差异有统计学意义(P<0.05)。结论对轻度持续哮喘患儿在社区实际生活条件影响下单用孟鲁司特仍可以有效控制哮喘症状的发作。

Objective To assess the effectiveness of montelukast as monotherapy on mild persistent asthma in children under real - life conditions. Methods A pilot, single and non - blind design was used in this study. Children aged 2 to 14 years old, with mild persistent asthma and treated in community were recruited. Four mg tablets of montelukast sodium were administered to patients aged ：2 to 5 years once daily, and 5 nag tablets to patients aged 6 to 14 years once daily for 12 consecutive weeks. The drugs were given to patients by their caregivers in communities. The continued treatment and evaluation were given in follow - up. Patients＇ severity score of day and nocturnal symptoms, the usage of short- acting 132 receptor agonist（SABA） and peak expiratory flow（PEF） were assessed at baseline and at 4, 8, and 12 weeks after the start of montelukast treatment. The data were analyzed by using SPSS 16.0 software. Results There were significant differences between each adjacent time group of daytime asthma symptom score and nighttime asthma score which decreased gradually each time （ P 〈 0.05 ）. Short - term usage of SABA decreased obviously and there was significant difference between baseline and week 4 in usage of SABA （ P 〈 0.05）. Peak expiratory flow improved, and there was significant difference between baseline and week 12 in PEF measurement （P 〈 0.05）. Conclusion These results suggest that montelukast is an effective monotherapy controller on mild persistent asthma in children under real - life conditions.